Discover the range of academic oncology titles at Springer Nature here.
This thematic series is currently open for submissions. Research studies and reviews on biomarkers for diagnosis, prognosis, and targeted therapy for cancer immunotherapy are welcome to the series. Novel and/or major advances in methodologies and materials for biomarker research will be also be considered. The submission deadline is September 30.
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Springer Nature Oncology Portfolio
Chung-Tsen Hsueh, Loma Linda University
Delong Liu, New York Medical College
Aims and scope
Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines. Read more.
Announcing the launch of In Review
Biomarker Research, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Annual Journal Metrics
30 days to first decision for reviewed manuscripts only
19 days to first decision for all manuscripts
72 days from submission to acceptance
15 days from acceptance to publication
On the blog
16 April 2021
19 February 2021